pan-Canadian Pharmaceutical Alliance (pCPA): September 2019 Trends and Insights
The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the September 30, 2019 status of brand negotiations. Highlights since the last update include:
- 4 products completed CADTH review, for a total of 6 files under consideration;
- 8 products initiated pCPA negotiations, for a total of 48 active negotiations;
- 6 negotiations completed for a total of 276 completed negotiations;
- 1 negotiation closed, for a total of 45 closed negotiations; and
- 1 file closed without negotiations, for a total of 69 declined negotiations.
Files Under pCPA Consideration
4 new drug products received a CDEC recommendation or pERC notification to implement in September 2019, for a total of approximately 6 products under pCPA Consideration.
| Brand Name | Generic Name | Manufacturer | Indication | Recommendation |
|---|---|---|---|---|
| Darzalex | Daratumumab | Janssen | Multiple Myeloma (newly diagnosed) | Conditional |
| Lonsurf | Trifluridine and Tipiracil | Taiho Pharma | Metastatic Colorectal Cancer |
Do Not Reimburse
|
| Iluvien | fluocinolone acetonide intravitreal implant | Knight Therapeutics | Diabetic Macular Edema |
Do Not Reimburse
|
| Dovato | dolutegravir/lamivudine | ViiV Healthcare | HIV-1 Infection | Conditional |
Negotiation Initiation
The pCPA initiated 8 new negotiations since the last update, for a total of 48 active negotiations.
| Brand Name | Generic Name | Manufacturer | Indication | CADTH Date | Time to Initiate |
|---|---|---|---|---|---|
| Keytruda | Pembrolizumab | Merck | Melanoma adjuvant therapy | 19 Aug 19 | 27 days |
| Lutathera | Lutetium Lu-177 | Advanced Accelerator Applications | Midgut neuroendocrine tumours | 19 Aug 19 | 27 days |
| Lenvima | Lenvatinib | Eisai | Unresectable hepatocellular carcinoma, first line | 9 Aug 19 | 37 days |
| Olumiant | Baricitinib | Eli Lilly | Rheumatoid Arthritis | 2 Aug 19 | 44 days |
| Verzenio | Abemaciclib | Eli Lilly | Advanced or metastatic breast cancer | 22 Jul 19 | 55 days |
| Revlimid | Lenalidomide | Celgene | Multiple myeloma | 5 Jul 19 | 72 days |
| Radicava | Edaravone | Mitsubishi Tanabe | Amyotrophic lateral sclerosis | 27 Mar 19 | 172 days |
| Truxima | Rituximab | Teva | Rheumatoid arthritis, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma | N/A | N/A |
*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.
Signals Decoded:
The number of files Under pCPA Consideration has been adjusted to remove (as of July 2019) Cinqair, Fasenra and Nucala. All 3 had received CADTH recommendations on March 27, 2019 based on a Request for Advice. Given recent updates to the ODB formulary, it appears that no new negotiations will be initiated for these products at this time, and that any administrative/criteria changes stemming from the Request for Advice, will be implemented at the jurisdictional level.
Completed
| Brand Name | Generic Name | Manufacturer | Indication | Initiated | Duration* |
|---|---|---|---|---|---|
| Blincyto | Blinatumomab | Amgen | Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia | Jul 2019 | 62 days |
| Opdivo | Nivolumab | BMS | Adjuvant treatment of melanoma | Jun 2019 | 92 days |
| Velphoro | Sucroferric oxyhydroxide | Vifor | Hyperphosphatemia in end stage renal disease | Apr 2019 | 153 days |
| Fulphila | Pegfilgrastim | BGP Pharma | Febrile neutropenia in non-myeloid malignancies | Feb 2019 | 212 days |
| Dupixent | Dupilumab | Sanofi Genzyme | Atopic Dermatitis | Nov 2018 | 304 days |
| Trelegy Ellipta | Fluticasone furoate + umecilidinium/vilanterol | GlaxoSmithKline | Chronic obstructive pulmonary disease | Nov 2018 | 304 days |
*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.
Closed
| Brand Name | Generic Name | Manufacturer | Indication | Initiation | Duration* |
|---|---|---|---|---|---|
| Trulicity | Dulaglutide | Eli Lilly | Type 2 Diabetes Mellitus | Jul 2017 | 792 days |
Signals Decoded:
September saw the completion of negotiations for new indications for Blincyto (4th) and Opdivo (5th). September also saw the closure of Trulicity – one of the two negotiations (other is Kuvan) that have been active for more than 2 years..
Not Negotiated
| Brand Name | Generic Name | Manufacturer | Indication | CADTH Date | Time to Decision* |
|---|---|---|---|---|---|
| Alunbrig | Brigatinib | Takeda | ALK positive locally advanced or metastatic non-small cell lung cancer | 19 Aug 19 | 27 days |
*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.
To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.
